Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Werewolf Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.95 · gapped above the open, then crossed back over prior close. High/low 0.96 at 6:00 am ET, 0.93 at 10:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We have engaged Piper Sandler & Co., or Piper Sandler, to serve as exclusive financial advisor to assist in the strategic review process.”
FILING10-K0001785530-26-000006cik 0001785530
“We have licensed from Harpoon certain patents that are directed to single immunoglobulin variable domains that bind human serum albumin.”
FILING10-K0001785530-26-000006cik 0001785530
“In March 2018, we entered into an assignment and license agreement, or the Harpoon Agreement, with Harpoon, pursuant to which we assigned to Harpoon certain patents related to adoptive cell therapies and binding moieties for conditional activation of immunoglobulin and non-immunoglobulin molecules, and Harpoon assigned to us certain patents related to certain inducible polypeptides and a binding moiety for conditional activation of certain polypeptides.”
FILING10-K0001785530-26-000006cik 0001785530
“For example, in April 2022, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha, or IFNα, INDUKINE molecule, JZP898, as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria.”
FILING10-K0001785530-26-000006cik 0001785530
“We have an exclusive option under our November 2022 collaboration agreement with Adimab LLC to acquire ownership of a patent family directed to our IL-18 INDUKINE molecules and our WTX-518 product candidate.”
FILING10-K0001785530-26-000006cik 0001785530
Watchlist prices, news filtered to it, and its next report on your desk.
Werewolf Therapeutics, Inc. has 4 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Werewolf Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
HOWL (Werewolf Therapeutics, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PIPR −2.06%, in financials.